本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
GUANGYUAN, CHINA - Media OutReach Newswire - 24 March 2025 - On March 12, marking the 47th Arbor Day of China, the "Shu Road Cuiyun Corridor Ancient Cypress Conservation Handover Ceremony" was held in Jian'ge County, Guangyuan City, Sichuan Province. More than a hundred town and township cadres, forest rangers and villagers witnessed this special handover event, who gathered to witness the transfer of responsibility for the stewardship of more than 12,000 ancient and famous trees. Among these venerable beings, the eldest boasts an impressive age of approximately 2,300 years. On March 15, Hope Justman (middle) and her friends strolling on the ancient Shu Road in Jiange County, Guangyuan City. Photo by Liu Ren Since the Ming Dynasty, Jian'ge County has upheld a tradition of conducting handover ceremonies for ancient cypresses along its trade routes during the transition between incoming and outgoing officials. As part of this practice, the officials meticulously count the number of ancient cypresses and record their survival and growth conditions in the area. To this day, the handover of ancient and famous trees remains a vital aspect of transfer of duty in Jian'ge County, symbolizing the enduring commitment to safeguarding these venerable trees across generations. Located in the northern part of Sichuan, Jian'ge County stands as a pivotal landmark along the ancient, a trade route boasting a history of more than 2,000 years. Renowned for its wealth of transportation relics and cultural landscapes that bear witness to the passage of time, it has earned the title of "a living fossil of ancient land transportation". As early as 2015, the ancient Shu Road was already added to the UNESCO World Heritage Tentative List, and has since been nominated as a candidate for both World Natural and Cultural Heritage status. Within the ancient Shu Road, a stretch of nearly 300 kilometers lies in Guangyuan City, Sichuan Province, renowned as the section with the most abundant relics and historical narratives. Particularly notable is the Cuiyun Corridor in Jian'ge County, which boasts the world's largest, oldest, and most extensive cluster of ancient trees planted along an historic route. Currently, a total of 7,803 ancient trees remain, including 7,778 ancient cypresses with an average age of 1,050 years. The verdant trees block out sunlight, creating an ethereal atmosphere that makes walking beneath them feel like stepping into a living painting. In recent years, the ancient Shu Road has gradually emerged as a sought-after destination among both Chinese and foreign tourists thanks to its unique charms. On March 13, 82-year-old American explorer Hope Justman, accompanied by her friends, explored iconic sites such as Jianmen Pass and the Cuiyun Corridor, immersing themselves in the rich culture of the Shu Road and the timeless grandeur of its ancient trees. This marked her 25th journey along this millennia-old historic route. To better protect the ancient and famous trees, local authorities perform "physical check-up" for them on a regular basis, including inspections for hollowing and decay, cleaning and treating damaged areas of trunks, and performing "minimally invasive surgeries". Over the past three years, Jian'ge County has successfully restored and rescued 2,478 endangered and weakened ancient cypresses. On March 15, China officially enacted the Regulations on the Protection of Ancient and Famous Trees, marking the first time the country has established standardized management and protection practices for these trees through administrative legislation. Notably, the Regulations drew inspiration from the ancient cypress handover system of the Cuiyun Corridor along the historic Shu Road. Cuiyun Corridor on the ancient Shu Road. Photo by Meng Libo Hashtag: #JiangeCountyThe issuer is solely responsible for the content of this announcement.
Hsinchu, Taiwan – March 20, 2025 – ACE Biotek unveiled its Spark Surgical Anesthesia System at the 2025 Kaohsiung SmartCity Summit & Expo, featured at the Smart Healthcare Pavilion. The company also participated in the Joint Commission of Taiwan’s “Smart Hospital Leadership Summit,” where it engaged with over a hundred hospital directors across Taiwan, promoting the vision of enhancing healthcare efficiency and reducing labor burdens through innovative healthcare solutions. Themed “Sustainability × AI = The New Future of Smart Healthcare,” the Smart Healthcare Pavilion gathered 18 medical institutions from Southern Taiwan, showcasing innovative achievements in competent healthcare across the central and southern regions. ACE Biotek’s Spark Surgical Anesthesia System, which integrates pre-, intra-, and post-operative anesthesia care forms, aims to enhance the digitalization level of anesthesia departments in hospitals across these regions. The interactive demonstration area attracted numerous healthcare professionals to experience the system firsthand. The event drew officials from various industries, academia, and the healthcare sector to the opening ceremony and nearly 200 international visitors. Many guests, such as Kaohsiung Deputy Mayor Lin Chin-Rong, the Ministry of Health and Welfare Director, Health Bureau representatives, and hospital IT managers, visited the ACE Biotek booth to explore the Spark Surgical Anesthesia System. By leveraging digital technologies, the system achieves structured data management and paperless processes, significantly improving healthcare efficiency and precision in collaboration. Additionally, it offers a comprehensive integration of anesthesia data throughout the surgical process, from physiological monitors to anesthesia machine data, providing real-time recording and seamless data flow. This high-level integration enables smooth interfacing with hospital HIS, surgical systems, and billing systems while combining medical AI and big data to enhance operational efficiency and accuracy, supporting hospitals in achieving efficient and standardized intelligent surgery management. In line with the Ministry of Health and Welfare’s vision for a next-generation digital healthcare platform, ACE Biotek is dedicated to developing practical, innovative hospital solutions tailored for domestic hospitals and promoting them internationally in countries such as Japan, the Middle East, and Southeast Asia. ACE Biotek’s Japan office in Izumi City will hold its grand opening ceremony on April 15, showcasing its commitment to global expansion. ACE Biotek will focus on implementing AI-powered innovative healthcare solutions and collaborating with Japanese medical institutions and partners to bring Taiwan’s imaginative hospital achievements to the international stage. About ACE Biotek Established in 2000, ACE Group has grown across wireless and healthcare industries for more than 20 years. Originally, ACE Group formed ACE Solution as its first foray to focus on wireless communication, networking hardware, and customized system integration projects. Driven by President Steve’s vision to improve healthcare quality, he built the ACE Biotek building from the ground up and officially founded ACE Biotek in 2018. ACE Biotek integrates the past 20 years of industrial experience and knowledge to solve unmet clinical needs. To achieve the early diagnosis of diseases, we have developed innovative medical solutions regarding imaging algorithms, cloud computing, artificial intelligence, and terahertz technology so far. In the long term, ACE Biotek will expand globally to serve as a platform to cultivate talents and support tech companies in transforming into Medtech. Contact ACE Biotek Advanced ACE Biotek Co., Ltd. Address: No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County 302, Taiwan (Hsinchu Biomedical Science Park) Phone: +886-3-5500909 E-mail: service@acebiotek.com Website: https://www.acebiotek.com/ Facebook: https://www.facebook.com/Acebiotek/ LinkedIn: https://www.linkedin.com/company/30620922/admin/
台灣新竹，2025年3月20日 – 筑波醫電開發Spark手術麻醉系統，受邀參加2025高雄智慧城市展於智慧醫療主題館中亮相，並參與醫策會「智慧醫院院長大會」，與全台超過百位醫院院長共同切磋交流，響應以智慧醫療提升照護效率、降低人力負擔。本次主題館以「永續×AI = 智慧醫療新未來」為主題，匯聚南台灣18家醫療院所，展示中南部智慧醫療的創新成果。筑波醫電Spark手術麻醉系統以「整合手術前、中、後麻醉護理表單」為特色，提升中南部醫院麻醉科的數位化水平，展會設有互動體驗區，吸引眾多醫界專業人士駐足。 本次活動吸引產、醫、學界的長官出席開幕儀式，並迎來全球近200位海外訪客。許多嘉賓如高雄副市長林欽榮、衛福部司長、衛生局、醫院資訊主管等親臨筑波醫電攤位，體驗Spark手術麻醉系統。該系統透過電子化技術實現數據結構化與無紙化管理，大幅提升醫療效率與協作精準度，為醫師、護理師及檢查人員帶來極大便利。此外，全面整合手術過程的麻醉數據，從生理監視器到麻醉機資料，實現即時記錄與完整數據流轉。透過高度整合能靈活對接醫院HIS、手術與批價系統，並結合醫療AI大數據，提升作業效率與準確性，助力醫院實現智慧手術的高效化與標準化管理。 為響應衛福部次世代數位醫療平台的宗旨，筑波醫電致力於開發可落地國內醫院的的智慧醫院系統方案，並已在日本、中東、東南亞等國家進行推廣。筑波醫電的日本辦事處位於出水市，將於4月15日舉行揭牌開幕式，展現公司國際化的步伐。未來將專注於將AI智慧醫療方案落地，並與日本醫療院所及合作夥伴攜手，將台灣智慧醫院的成果推向國際。 關於筑波醫電ACE Biotek 筑波醫電大樓是董事長許深福先生驅動內心的寄望及理念，依據建築設計師、施工團隊及同仁們很科學的作品。是筑波人多年來文化、創意技術的展現，是筑波全體同仁長久對生醫產業接軌國際平台的堅持。筑波科技集團以豐富的無線通訊軟硬體整合經驗、結合半導體晶片、醫學影像演算法、雲端技術、人工智慧、臨床醫師專業、法規驗證與專利技術綜效，著力於人們早期病變篩檢系統的精準醫療設備產品研發與生產。期望不但可以減少病患及家人的遺憾，並開拓台灣本土精密無創微創醫檢設備能量且推廣於國際，更建立台灣從3C到三醫(醫才、醫技、醫材)的產業鏈轉型平台與人才的培育之目標。 連絡筑波醫電 筑波醫電股份有限公司Advanced ACE Biotek Co., Ltd. 地址：30261新竹縣竹北市生醫二路66號 (新竹生醫園區) 電話: +886-3-5500909 E-mail: service@acebiotek.com 網站: https://www.acebiotek.com/ Facebook: https://www.facebook.com/Acebiotek/ LinkedIn: https://www.linkedin.com/company/30620922/admin/
BEIJING, Oct. 25, 2024 /PRNewswire/ --Chindata Group officially unveiled its latest innovation, the AI Data Center Total Solution 2.0, at the 2024 China Computing Power Conference. Designed to meet the growing demands of artificial intelligence (AI) workloads, the solution addresses critical challenges such as high-density cabinets, hyperscale facilities, and heterogeneous computing environments. The launch took place during the Data Center Technology Innovation and Transformation Forum, co-hosted by Chindata Group and the China Academy of Information and Communications Technology (CAICT). Held at the same conference, the forum brought together industry leaders from CAICT, China Telecom, Intel, Baidu, Alibaba Cloud, Inspur, Seagate Technology, and others to explore the latest advancements in intelligent computing and IT infrastructure for the AI era. Addressing Evolving Demands in AI Workloads The sharp rise in power consumption among GPUs and servers has led to data center clusters scaling beyond hundreds of megawatts. These trends present new challenges for traditional data center operations. As a leading data center operator, Chindata Group has developed a proactive strategy to address the increasing demand for computing power. The AI Data Center Total Solution 2.0 incorporates advanced prefabrication and modular building models, the innovative "X-Power" power system, the "X-Cooling" cooling solutions, and an AI-driven comprehensive operation and maintenance platform. This state-of-the-art solution is designed to support the accelerated growth of artificial intelligence and ensure high-quality and flexible business operations for customers. Key Features of AI Data Center Total Solution 2.0 1. Flexible Prefabrication and Modular Construction: Prefabrication and modular construction models are capable of being arranged and manufactured in various stages, which allows for the agile deployment of business operations while accommodating a wide range of hardware configurations, including CPUs and different types of AI accelerators. This modularity improves IT performance per square unit and addresses the growing high-density requirements of AI technologies. This solution delivers a fast, efficient response to the need for high computing power in the era of large models and general artificial intelligence (AGI). Utilizing this construction methodology, a hyperscale project can be completed and handed over to the client within 6 months in China, and within 8 months across the rest of the Asia-Pacific region. 2. X-Power Modular Power System: The upgraded "X-Power" system integrates over ten traditional components of power distribution into six primary modules: substations, generators, medium voltage units, low voltage units, batteries, and IT support equipments. These modules can be deployed in phases according to specific needs, allowing for flexible and scalable expansion. By reducing complexity, this system enhances power efficiency and accelerates the delivery of hyperscale facilities while maintaining the highest quality standards. The X-Power system is capable of supporting server cabinets with power densities of up to 132kW, providing robust power capacity for the most demanding AI and high-performance computing. 3. X-Cooling Solutions: The "X-Cooling" solutions offer comprehensive cooling systems that combine air cooling, liquid cooling, and hybrid cooling methods to address the high-density demands of AI-ready data centers. With capabilities ranging from cabinet power densities of 8kW to 150kW, and achieving a PUE as low as 1.10 with immersive liquid cooling, this solution integrates multiple cooling technologies and products, adapting to architectural, environmental, and geographical constraints. As traditional air cooling methods reach their limits in high-density environments, there is an increasing demand for liquid cooling in hyperscale data centers. In response, Chindata has initiated the development of industry standards for cold plate liquid cooling systems in China, leveraging the experience gained from developing and deploying X-Cooling solutions. These standards will ensure quality control throughout the lifecycle of the systems. 4. AI-Driven Operations and Maintenance: Chindata's integrated monitoring platform, combined with its data center operational management system, enables more automated and standardized management processes. By incorporating AI-driven solutions, the platform optimizes the control of critical systems, particularly the cooling systems, ensuring maximum efficiency and reliability. Chindata continues to refine its operation and maintenance protocols to meet the evolving demands of AI data centers. Industry Leadership in AI Infrastructure Zhang Binghua, Chief Technology Officer at Chindata Group, commented on the launch: "The rise of AI is fundamentally transforming the landscape of data center technologies. Chindata has always been committed to leading technological innovation, focusing on modularity, integration, and advanced prefabrication. With the AI Data Center Total Solution 2.0, we are well-positioned to meet the diverse computing needs of the AI era, ensuring the efficient translation of electrical energy into computational power." About Chindata Group Chindata Group is a leading carrier-neutral hyperscale data center solutions provider in the Asia-Pacific region, pioneering next-generation hyperscale data centers in China, India, and Southeast Asia. The company offers end-to-end services across the facility lifecycle, including planning, investment, design, construction, and operation. With a robust international development team, Chindata is expanding its data center clusters in Malaysia, India, and Thailand, and seeking further business opportunities in emerging markets across Asia-Pacific. For media inquiries, please contact: media@Chindatagroup.com
The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse events; The China new drug application submission is expected in Q2 2024, while ex-China product development is in active progress. SHANGHAI, March 19, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical leader in the discovery, development, and commercialization of innovative drugs for genitourinary tumors and related diseases announced that the multicenter Phase III global clinical study data of its non-surgical treatment for cervical HSIL product APL-1702 demonstrated significant efficacy and good safety profile, with new advancements in clearance rate of high-risk HPV16 and/or HPV18. Key data from the study were presented in oral presentations at the 2024 European Research Organization on Genital Infection and Neoplasia (EUROGIN) Congress and the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting. APL-1702 is a pioneering cold light photodynamic drug-device combination product, used as a non-surgical therapy for treating cervical HSIL. This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL. Primary endpoint of the study is the proportion of responders at 6 months after the initial treatment. The study is led by Dr. Jinghe Lang, an academician at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences. Response is defined as the conversion of cervical epithelial tissue pathology to normal or the conversion to low-grade squamous intraepithelial lesion (LSIL) while achieving baseline HPV clearance. According to the study results, between November 2020 and July 2022, a total of 402 eligible patients from various countries including China, Germany, the Netherlands et al. were randomized and enrolled in this study. The response rate in the APL-1702 treatment group showed a statistically significant improvement of 89.4% (41.1% vs. 21.7%, p = 0.0001) compared to that in the placebo control group, indicating a remarkable therapeutic effect. Additionally, APL-1702 showed an improved clearance rate of high-risk HPV16 and/or HPV18, with a 103.9% increase in the APL-1702 treatment group compared to the control group (31.4% vs. 15.4%)[1]. The incidence of treatment-emergent adverse events (TEAEs) was comparable between the treatment group and the control group, with the majority being mild and self-healing without requiring intervention. The occurrence rates of treatment-related adverse events (TRAEs) and serious adverse events (SAEs) were both low in both groups[2]. According to the "Global Cancer Statistics 2020" report, there were 604,127 new cases of cervical cancer in women worldwide in 2020, with 341,831 deaths, ranking it as the fourth most common cancer among women. Cervical cancer incidence ranks second among malignant tumors in Chinese women. According to the "National Cancer Report 2024" released by the National Cancer Center, there were 150,700 new cases of cervical cancer in China in 2022, with 55,700 deaths from cervical cancer. The main cause of cervical cancer is persistent infection with human papillomavirus (HPV), which leads to precancerous lesions of the cervix. Approximately 25% of individuals with HSIL may progress to invasive cervical cancer within 10 years[3]. According to Frost Sullivan analysis, it is projected that by 2030, the number of HSIL patients worldwide and in China will reach 16.6 million and 2.2 million, respectively. With the increasing popularity of dual-cancer screening and cervical cytology tests, more and more patients with cervical precancerous lesions are being detected at early stages before cancer develops, and it is expected that the number of patients will continue to increase. Women with cervical precancerous lesions have unmet clinical needs for non-surgical therapies. Currently, invasive procedures such as loop electrosurgical excision procedure (LEEP) and cold knife conization remain the primary treatment options for high-grade cervical lesions. However, these surgical treatments are associated with adverse reactions including bleeding, infection, and cervical structural damage, which may lead to complications such as preterm birth and miscarriage. Furthermore, cervical precancerous lesions require long-term monitoring and management because even after surgical treatment, there is a risk of persistent disease or recurrence, with a higher risk of developing cervical cancer compared to the general population (5 times higher risk of invasive cancer within 10 years). Therefore, post-operative follow-up for at least 25 years is necessary. Importantly, if cervical precancerous lesions recur, subsequent surgical interventions become more challenging and carry higher risks, potentially resulting in total hysterectomy. Thus, early surgical intervention increases the difficulty of long-term management. Non-surgical therapies that preserve the intact cervix and avoid or delay cervical trauma are of significant importance for the long-term management of patients with cervical precancerous lesions. Professor Chen Fei, Chief Physician of the Department of Obstetrics and Gynecology at Peking Union Medical College Hospital, expressed her delight with the research findings, stating, "I am extremely pleased with the results of this study. Treating HSIL serves as the final barrier against cervical cancer. Previous international studies on HSIL have not been successful, but this study, utilizing a multicenter trial design and strict definition of efficacy endpoints, has achieved positive results, which is no easy feat. As a clinician, I have encountered many HSIL patients who desire to preserve their intact cervix while receiving treatment. The emergence of APL-1702 will fulfill the wishes of these patients, allowing them to avoid or delay cervical trauma to the maximum extent possible." Professor Qiao Youlin, a member of the WHO Global Expert Group for Cervical Cancer Elimination and a professor at the School of Population Medicine and Public Health at the Chinese Academy of Medical Sciences/Peking Union Medical College, believes that in addition to vaccination and screening, treatment of cervical precancerous lesions is a crucial component of secondary prevention for cervical cancer. However, progress in the field of medication for cervical precancerous lesions has been relatively slow, with high barriers to overcome, and there are currently no approved treatment drugs worldwide. "It is gratifying to see the emergence of innovative products like APL-1702, which simultaneously possess clinical value in addressing the treatment gap, public health value in cervical cancer prevention and control, and social value in promoting fertility-friendly options. This breakthrough will safeguard women's health and make a positive contribution to the acceleration of the 2030 global and Chinese action plans for cervical cancer elimination". Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, "We are extremely proud of the results from the international multicenter Phase III clinical study of APL-1702. The study not only demonstrates remarkable efficacy but also exhibits a favorable safety profile, offering a new powerful artillery for the national cervical cancer prevention and control system. We express our gratitude to all the patients, physicians, and researchers who participated in this study, as their support and dedication have been invaluable. We are actively preparing the new drug application for APL-1702 and plan to submit it in the second quarter of this year. Additionally, we are making significant progress in product development overseas, aiming to bring this innovative treatment to more patients as soon as possible." References： EUROGIN: Photodynamic therapy with APL-1702 for high-grade squamous intraepithelial lesions (HSIL): results from a randomized phase Ⅲ global study (YHGT-CEV-1/APRICITY) SGO: APL-1702 long-term efficacy and safety for cervical histologic high-grade squamous intraepithelial lesions (HSIL): results from a randomized phase Ⅲ global study Gao Shujun, Sui Long. Standardized management and follow-up of high-grade squamous intraepithelial lesions of the cervix[J]. Chinese Journal of Practical Gynecology and Obstetrics. 2020,36(07):604-608. About APL-1702(Cevira®) APL-1702(Cevira®) is a breakthrough photodynamic drug-device combination product that is being developed for non-surgical treatment of high-grade precancerous lesions of the cervix. Cevira® holds the potential to serve the high unmet medical need for non-invasive treatment options for patients with HSIL in an outpatient setting, especially for young women of reproductive age. Asieris Pharmaceuticals entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to obtain the worldwide development and commercialization of Cevira® in July 2019. Cevira® is a registered trademark of Photocure ASA, based in Oslo, Norway. About Asieris Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health to preserve patient's dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide. The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus. Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.
PALO ALTO, Calif., Jan. 30, 2024 /PRNewswire/ -- Announcing the integration of Linux SDN at the OpenSync Summit in March 2023 marked a significant stride for OpenSync, extending its reach to cover all smart home devices. Now, with the live release of OpenSync 5.6 in December 2023, the OpenSync framework seamlessly integrates support for Linux SDN. Liem Vo, Chief OpenSync Officer OpenSync has extended support for the widely adopted Linux networking bridge, eliminating the need for additional development effort previously required to convert from the Linux bridge to OpenvSwitch (OVS). As a result of this expansion, OpenSync extends its reach to 100% of smart home devices, maintaining its position as the only software defined networking framework for consumer premise equipment. The support of Linux SDN, from OpenSync 5.6, enhances the ease of adoption for OpenSync. It has already been embraced by ZTE and Evolution Digital, TP-Link, Wistron NeWeb Corporation (WNC), Heights Telecom will be adopting OpenSync with Linux SDN. "OpenSync now supporting Linux SDN represents a fundamental shift, going beyond mere complexity reduction to reshaping possibilities. OpenSync integration has become easier and faster. Compatibility soars seamlessly with the Linux native bridge, enabling faster time to market. This is a transformative journey where OpenSync is poised to be available wherever connectivity thrives, quickly, scalably, and reliably." - Liem Vo, Chief OpenSync Officer Why is Linux SDN a Game-Changer? Experience the Power. Simplified Integration: Linux SDN significantly reduces the complexity and effort required to integrate OpenSync, facilitating a smoother and faster process, enabling a faster time to market. Enhanced Compatibility: Seamless operation with the Linux native bridge, making it accessible to a wider range of hardware and development options. Barrier-Free Integration: OpenSync integration has never been easier, eliminating the hard dependency on OpenvSwitch and the need to learn OVS. Join us in embracing the future of connectivity with Linux SDN support. Download today! About OpenSync: OpenSync is the only open-source software-defined networking (SDN) framework that transforms how services are managed and delivered from a cloud control plane. With over 2.5 billion connected devices, OpenSync provides a complete framework for Communication Service Providers (CSPs), Original Device Manufacturers, (ODMs,) consumer device manufacturers, and cloud service developers to deliver smart home residential and intelligent small business services quickly, scalably, and reliably. By decoupling services from hardware and utilizing standardized management APIs, OpenSync fosters an ecosystem of diverse customer premise equipment (CPEs). OpenSync seamlessly integrates with industry-standard Software Development Kits (SDKs) like RDK-B and OpenWRT, and boasts wide compatibility with all major silicon vendors. The vibrant OpenSync community fosters collaboration, innovation, and knowledge-sharing. Join us on this transformative journey towards the future of service delivery, today. For more information, visit www.opensync.ioFollow OpenSync on LinkedIn OpenSync PR Contact (U.S.)Sarah HeerenOpenSyncsarah@opensync.io
Standardized Management
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
